Vemurafenib

In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation.

Saved in:

Bibliographic Details
Published in:	Nature reviews. Drug discovery Vol. 10; no. 11; pp. 811 - 812
Main Authors:	Flaherty, Keith. T, Yasothan, Uma, Kirkpatrick, Peter
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01.11.2011 Nature Publishing Group
Subjects:	631/154 67 692/699/67/1813/1634 Animals Biomedical and Life Sciences Biomedicine Biotechnology Cancer Cancer Research Care and treatment Clinical trials Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Drug therapy fresh-from-the-pipeline Humans Indoles - pharmacology Indoles - therapeutic use Medicinal Chemistry Melanoma Melanoma - drug therapy Melanoma - enzymology Melanoma - genetics Metastasis Molecular Medicine Pharmacology/Toxicology Physiological aspects Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins B-raf - metabolism Ras genes Sulfonamides - pharmacology Sulfonamides - therapeutic use Vemurafenib
ISSN:	1474-1776, 1474-1784, 1474-1784
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation.
Bibliography:	SourceType-Scholarly Journals-1 ObjectType-News-1 content type line 14 content type line 23
ISSN:	1474-1776 1474-1784 1474-1784
DOI:	10.1038/nrd3579